Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Lilly’s Baqsimi Hits Japan Market, 1st Glucagon Nasal Powder
October 5, 2020
- AstraZeneca’s COVID-19 Vaccine Trial Resumes in Japan
October 5, 2020
- Chugai Seeks Label Expansion for FoundationOne as CDx for Pemigatinib, Larotrectinib
October 5, 2020
- Kyowa Kirin Commences Japan PII of Zandelisib for Indolent B-Cell Non-Hodgkin’s Lymphoma
October 5, 2020
- Novartis’ Tabrecta Hits Snag in Japan on Hospitals’ CDx Reimbursement Issue
October 2, 2020
- Maruishi to Discontinue Precedex after Pfizer Pact Expires
October 2, 2020
- UCB Japan Goes Solo on E Keppra Marketing as Otsuka Deal Ends
October 2, 2020
- Fujifilm to Manufacture VLP Therapeutics’ COVID-19 Vaccine
October 2, 2020
- ASKA, Kyorin to Jointly Develop Benign Prostatic Hyperplasia Drug
October 1, 2020
- Eisai, Seikagaku Tie Up on Osteoarthritis Med in South Korea
October 1, 2020
- Mitsubishi Tanabe Recalls Theodur on Failed Dissolution Test
October 1, 2020
- Shionogi Grabs Global Rights for Univ. of Tokyo Spin-Off’s Novel S. Pneumoniae Nasal Vaccine
October 1, 2020
- After Photoimmunotherapy Nod, Rakuten’s Mikitani Says Company Is Finally at Start Line
September 30, 2020
- Fetroja Approved for Nosocomial Pneumonia in US
September 30, 2020
- Fujifilm Kyowa Kirin’s Avastin Biosimilar Approved in Europe
September 30, 2020
- Torii Enjoys Stellar Performance from Corectim, 1st JAK Med for Atopic Dermatitis
September 30, 2020
- Alnylam Seeks Japan Approval of RNAi Drug Givosiran for Acute Hepatic Porphyrias
September 30, 2020
- JCR Files Sakigake-Designated Pabinafusp Alfa for Hunter Syndrome
September 30, 2020
- 2nd GPCR-Targeted Candidate Enters Clinic under Sosei/Pfizer’s Drug Discovery Alliance
September 29, 2020
- Otsuka Files Japan NDA for Atopic Dermatitis Drug Difamilast
September 29, 2020
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…